Figure 8.

Anti-tumor effects of combination therapy in a 4T1 orthotopic injection model. (a) Schematic of the therapeutic regimen. 2 × 10⁴ 4T1 tumor cells were injected orthotopically in the mammary fat pad of BALB/c mice on day 0, and all treatments began 7 days after tumor injection. (b) There was no obvious decrease in body weight weight of mice in response to the treatments. (c) Mice (n = 5) were euthanized, and tumor weights were measured on the 26th day. (Vec group = 2.208 ± 0.3231; Dox group = 1.330 ± 0.2852; OsFS group = 1.116 ± 0.1372; Dox+OsFS group = .5120 ± 0.1547). (d) Survival time was monitored for 56 days (n = 8). Mean survival times were as follows: Vector (Vec) group = 31.1 days; OS group = 35.9 days; OsF group = 38.6 days; OsFS group = 47.8 days. (e) Splenocytes from vaccinated tumor-bearing mice were stimulated with FAPα peptides, survivin peptides, and unrelated human MUC1 peptides. The frequencies of IFN-γ-producing T cells were measured by ELISpot assays. (f-i) The proportions of CD3⁺CD8⁺ T cells (in CD45⁺ cells) (f), Tregs (in CD4⁺ cells) (g), MDSCs (h), and TAMs (F4/80⁺CD206⁻ M1 and F4/80⁺CD206⁺ M2) (i) infiltrated into tumors. (*P < .05, **P < .01, ***P < .001, ****P < .0001).